Transient YAP/TAZ inhibition exposes therapeutic vulnerabilities in advanced cancers [ATAC-seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · mouse · 11 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Mus musculus (mouse)
- Samples
- 11 samples: 6 × [ATAC-Seq] shYT#2 vs 5 × [ATAC-Seq] shRenGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE301500_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1285344 and SRA study SRP597423. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 11 samples.
How we read this: 2 replicated groups read from 11 sample titles; they account for 11 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9084202 [ATAC-Seq] shRen_1 [ATAC-Seq] shRen
- GSM9084203 [ATAC-Seq] shRen_2 [ATAC-Seq] shRen
- GSM9084204 [ATAC-Seq] shRen_3 [ATAC-Seq] shRen
- GSM9084205 [ATAC-Seq] shRen_4 [ATAC-Seq] shRen
- GSM9084206 [ATAC-Seq] shRen_5 [ATAC-Seq] shRen
- GSM9084207 [ATAC-Seq] shYT#2_1 [ATAC-Seq] shYT#2
- GSM9084208 [ATAC-Seq] shYT#2_2 [ATAC-Seq] shYT#2
- GSM9084209 [ATAC-Seq] shYT#2_3 [ATAC-Seq] shYT#2
- GSM9084210 [ATAC-Seq] shYT#2_4 [ATAC-Seq] shYT#2
- GSM9084211 [ATAC-Seq] shYT#2_5 [ATAC-Seq] shYT#2
- GSM9084212 [ATAC-Seq] shYT#2_6 [ATAC-Seq] shYT#2
- GSE301496 Transient YAP/TAZ inhibition exposes therapeutic vulnerabilities in advanced cancers [CUT&Run] 20 samples shares yap, taz, vulnerabilities, therapeutic, inhibition, transient, advanced
- GSE277188 Decoding the YAP/TAZ–PPARγ Regulatory Axis in Adipocyte Differentiation and Dedifferentiation [ChIP-seq] 46 samples shares yap, taz
- GSE301501 Extracellular matrix reprogramming by the YAP/TAZ/TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models 45 samples shares yap, taz
- GSE265949 Effect of endothelial YAP/TAZ on neuroinflammation and outcome after ischemic stroke in mice 16 samples shares yap, taz
- GSE327565 Sustained Yap/Taz activation promotes aberrant alveolar epithelial cell differentiation and drives persistent fibrotic remodeling 14 samples shares yap, taz
- GSE264594 The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia (ATAC-Seq) 9 samples shares vulnerabilities, atac-seq
- GSE296145 SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and TLR pathway therapeutic vulnerabilities 36 samples shares vulnerabilities, therapeutic
- GSE303692 A plastic EMP1⁺ to LGR5⁺ cell state conversion as a therapeutic bypass to KRAS-G12D inhibition in metastatic colorectal cancer [RNA-Seq] 24 samples shares therapeutic, inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.